ARTICLE | Company News

Daiichi and MD Anderson partner to develop AML candidates

October 27, 2017 6:57 PM UTC

Daiichi Sankyo Co. Ltd. (Tokyo:4568) and the University of Texas MD Anderson Cancer Center (Houston, Texas) partnered to develop multiple therapies for acute myelogenous leukemia (AML). During the multiyear collaboration, MD Anderson is to conduct multiple Phase I and Phase II trials, including combination studies and trials using biomarkers, of compounds in Daiichi's pipeline, including quizartinib (AC220), DS-3032, DS-3201b and PLX51107.

Quizartinib, an oral small molecule inhibitor of FMS-like tyrosine kinase 3 (FLT3; CD135), is in Phase III testing to treat AML...